InvestorsHub Logo
Followers 45
Posts 18382
Boards Moderated 0
Alias Born 09/16/2012

Re: IkeEsq post# 358042

Friday, 02/26/2021 1:31:08 PM

Friday, February 26, 2021 1:31:08 PM

Post# of 732491
Why rush? Is that what this is...rushing? Other biotech companies have built facilities in a year. Nevertheless, Powers and Toucan will make a great deal of money if they can get Advent up to speed for Advent's sake. Again, gearing up for dc production does not equate to DCVAX approval. We know German clinics and other places are using dc's already.


The reality is everyone except legacy common shareholders have already made a great deal of money, even without approval.

The company has in the past flooded the market with many rosy PR's and statements that ultimately never held together. Now they have the SEC looking around at something so...

You should be able to see the kind of cash warrant holders have and are making through shorting and pumping all these years, but you refuse to see it for some reason.

Many biotechs have run decades long trial with leading oncology practitioners and have either failed or even vanished. Again, failure of this particular trial will be devastating for common retail shareholders but not so much for management, as they can continue on with DCVAX private use and building their privately owned manufacturing facilities.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News